C170 (Darifenacin Hydrobromide Extended-Release 7.5 mg (base))
Pill with imprint C170 is Yellow, Round and has been identified as Darifenacin hydrobromide extended-release 7.5 mg (base). It is supplied by Par Pharmaceutical, Inc..
Darifenacin is used in the treatment of overactive bladder; urinary incontinence and belongs to the drug class urinary antispasmodics. Risk cannot be ruled out during pregnancy. Darifenacin 7.5 mg (base) is not a controlled substance under the Controlled Substances Act (CSA).
Images for C170
Darifenacin hydrobromide extended-release
- Imprint:
- C170
- Strength:
- 7.5 mg (base)
- Color:
- Yellow
- Shape:
- Round
- Availability:
- Prescription only
- Drug Class:
- Urinary antispasmodics
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Labeler / Supplier:
- Par Pharmaceutical, Inc.
- National Drug Code (NDC):
- 10370-0170
More about darifenacin
- Darifenacin Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 20 Reviews
- Drug class: urinary antispasmodics
Consumer resources
Other brands: Enablex
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2018 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
